Company intelligence / Profile preview
EffRx Pharmaceuticals
Freienbach, Schwyz, Switzerlandeffrx.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Commercial
01
Overview
EffRx has successfully developed and commercialized multiple products including Binosto for osteoporosis (with approximately 30 marketing authorizations worldwide), Alkindi for pediatric adrenal insufficiency, and Efmody for congenital adrenal hyperplasia. The company also has Miglustat Dipharma for Lysosomal Storage Diseases in its portfolio.
- Therapeutic areas
- EndocrinologyRare DiseasesRheumatology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Radius Health (for Binosto)Diurnal Group (for Efmody)
Beyond the preview
Go deeper on EffRx Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EffRx Pharmaceuticals.